Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | NQO1 | P15559 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28789679 | 0.97 | HPGD (0.50) | HPGDSMN1; SMN2LRRK2GRM5NQO1 | |
| SCHEMBL16579445 | 0.89 | HPGD (0.45) | HPGDSMN1; SMN2LRRK2GRM5NQO1 | |
| SCHEMBL2490706 | 0.84 | HPGD (0.45) | HPGDSMN1; SMN2LRRK2GRM5NQO1 | |
| SCHEMBL11509960 | 0.82 | HPGD (0.44) | HPGDSMN1; SMN2LRRK2GRM5NQO1 | |
| SCHEMBL28863144 | 0.82 | HPGD (0.44) | HPGDSMN1; SMN2LRRK2GRM5NQO1 | |
| SCHEMBL2585538 | 0.82 | SMN1; SMN2 (0.44) | HPGDSMN1; SMN2LRRK2GRM5NQO1 | |
| SCHEMBL2586207 | 0.78 | SMN1; SMN2 (0.41) | HPGDSMN1; SMN2LRRK2GRM5NQO1 | |
| SCHEMBL21725564 | 0.78 | SMN1; SMN2 (0.41) | HPGDSMN1; SMN2LRRK2GRM5NQO1 | |
| SCHEMBL430323 | 0.78 | HPGD (0.41) | HPGDSMN1; SMN2LRRK2GRM5NQO1 | |
| SCHEMBL11437617 | 0.78 | SMN1; SMN2 (0.43) | HPGDSMN1; SMN2LRRK2GRM5NQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455698-B1 | FOR TREATING CEREBRAL ISCHEMIA OR CEREBRAL INFARCTION RESULTING FROM THROMBOEMBOLIC OR HEMORRHAGIC STROKE, CEREBRAL VASOSPASMS, HYPOGLYCEMIA, CARDIAC ARREST, NEURODEGENERATIVE DISORDERS | WARNER-LAMBERT COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-20020065415-A1 | Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents | KORNBERG BRIAN EDWARD (US) | 2002-05-30 | — | — | US | disclosed |
| US-6340758-B1 | DRUGS AS NEUROPROTECTIVE AGENTS INVENTION MAY ALSO BE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA, EPILEPSY, ANXIETY, PAIN AND DRUG ADDICTION. | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065415-A1 | Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents | CBR1, CBR3, CHRNA7 | HPGD 938/4885SMN1; SMN2 201/4885LRRK2 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.